Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna specialty medication quantity limits – Cover…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy N/A

    Medical specialty medication quantity limits (selected agents)

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines maximum dosing regimens and authorized indications (quantity limits) for specialty medications (examples: Actemra/tocilizumab, Adcetris/brentuximab vedotin, IVIG products, bevacizumab) effective 4/1/2026. Applies to Aetna medical specialty medication management for covered members/providers.

    Policy Summary
    PayerAetna
    PolicyMedical specialty medication quantity limits (selected agents)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review Date
    Key ActionWhen requesting coverage, document the diagnosis and match the requested dosing regimen to the listed maximum dosing regimens (obtain prior authorization if requesting doses or frequency outside these limits).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4/1/2026Effective date
    dosage+routeDose + route
    weight bandsPediatric weights
    multipleIndications

    Coverage Criteria — Maximum Dosing and Quantity Limits

    inv-01: Initial and indication-specific dosing / quantity limits

    Covered when ALL of the following are met for the specific agent/indication:

    Actemra - Acute Graft Versus Host Disease: Route: IV; 8 mg/kg every 2 weeks.

    [[chunk 0]]

    Actemra - Castleman Disease: Route: IV; 8 mg/kg every 2 weeks.

    [[chunk 0]]

    Actemra - Cytokine Release Syndrome: Route: IV; ≥2 years: <30 kg 12 mg/kg (max 800 mg) up to 4 doses given ≥8 hours apart; ≥30 kg 8 mg/kg (max 800 mg) up to 4 doses given ≥8 hours apart.

    [[chunk 0]]

    Actemra - Giant Cell Arteritis: Route: IV; ≥18 years 6 mg/kg (max 600 mg) every 4 weeks.

    [[chunk 0]]

    Coding and Dosing Highlights

    Coding presencemixed
    not providedThe chunks list diagnoses/indications and dosing but do not include explicit CPT/HCPCS/NDC or ICD-10 codes in these excerpts.
    Weight-based pediatric dosing thresholds
    Weight bandsPediatric weight thresholds used for dosing decisions: <30 kg and ≥30 kg (examples: tocilizumab CRS dosing; multiple agents use similar bands)
    Pediatric JIA dosing exampleActemra (tocilizumab) polyarticular/oligoarticular JIA: ≥2 years: <30 kg 10 mg/kg every 4 weeks; ≥30 kg 8 mg/kg every 4 weeks
    CRS dosing example (pediatric weight-based)Actemra (tocilizumab) for cytokine release syndrome: ≥2 years: <30 kg 12 mg/kg (max 800 mg) up to 4 doses; ≥30 kg 8 mg/kg (max 800 mg) up to 4 doses
    Intravitreal pediatric dose for Retinopathy of Prematurity

    Provider Actions — Prior Authorization, Documentation, and Denial Risk

    Prior Authorization

    Follow listed dosing/regimen limits

    Follow the listed diagnosis-specific dosing and regimen limits in the Medical Specialty Medication Quantity Limits (effective 4/1/2026). Providers should adhere to the maximum dose, frequency, and minimum re-treatment intervals shown for each drug and indication. If the requested regimen exceeds the listed limits (dose, mg/kg, frequency, or earlier-than-allowed re-treatment), the request may be subject to denial or require prior authorization.

    • The quantity limits define per-treatment maximum doses and minimum re-treatment intervals (examples: botulinum products — no re-treatment sooner than every 12 weeks; IVIG product-specific regimens and intervals).
    • Prescribing and administration must follow the diagnosis-specific maximum dosing regimens (including age- and weight-based dosing where specified).
    • Providers intending to use dosing, frequency, or re-treatment intervals that exceed these limits should request prior authorization that matches the diagnosis-specific dosing regimen being sought.
    Prior Authorization

    Prior authorization must match dosing limits

    Prior authorization determinations, when applicable, should reflect the maximum diagnosis-specific dosing regimens and re-treatment intervals shown in the quantity limits effective 4/1/2026. Requests that propose greater doses, more frequent dosing, or earlier re-treatment than those listed should include a prior authorization request that documents the clinical rationale and matches the dosing being requested.

    Background — Scope and Purpose

    This section provides payer‑specified maximum dosing regimens tied to specific diagnoses for specialty medications. Entries include per‑diagnosis routes, dose amounts (fixed or weight‑based), and dosing frequency or re‑treatment intervals for multiple specialty agents — examples include tocilizumab (Actemra) dosing by indication and weight bands, intravenous immune globulin products (Asceniv and others) with indication‑specific regimens (for example, 2 g/kg divided over 2–5 days for many conditions), and botulinum toxin and ophthalmic biologics with unit or per‑eye limits and minimum re‑treatment intervals.

    Providers should note that these entries define the maximum authorized dosing regimens and quantity limits effective 4/1/2026. Prescribers requesting coverage should document the specific diagnosis, the intended dosing regimen (including patient weight when weight‑based dosing is specified), and the proposed schedule. If the intended dosing or frequency falls outside the listed maximums, providers should expect to pursue prior authorization consistent with payer processes and supply supporting documentation that justifies deviation from the listed limits.

    Definitions and Key Terms

    Maximum Dosing Regimen
    Maximum Dosing Regimen definitionThe highest authorized dose and administration frequency for a given diagnosis and route as listed in the document (entries effective 4/1/2026)
    Initial vs maintenanceSome entries distinguish an initial (induction) dosing series and subsequent maintenance dosing schedules (e.g., IVIG products)
    Routes coveredRegimens specify route of administration (IV, SC, intravitreal) alongside dose and frequency
    Maximum cumulative dose per 12-week interval
    Maximum cumulative dose per 12-week interval (botulinum example)Policy notes highest total amount permitted across all treated indications within a 12‑week period (e.g., OnabotulinumtoxinA adult maximums up to 400 Units per treatment; cumulative limits referenced in context)
    Re‑treatment interval

    Revision History

    2026-04-01policy_effectiveLatest

    Policy maximum dosing regimens and quantity limits became effective on 4/1/2026 for the listed specialty medications and indications.

    Policy Summary
    PayerAetna
    PolicyMedical specialty medication quantity limits (selected agents)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review Date
    Key ActionWhen requesting coverage, document the diagnosis and match the requested dosing regimen to the listed maximum dosing regimens (obtain prior authorization if requesting doses or frequency outside these limits).
    SourceLink
    On This Page
    Coverage Criteria — Maximum Dosing and Quantity LimitsCoding and Dosing HighlightsProvider Actions — Prior Authorization, Documentation, and Denial RiskBackground — Scope and PurposeDefinitions and Key TermsRevision History
    Actemra - Immune Checkpoint Inhibitor–Related Toxicities: Route: IV; 8 mg/kg every 4 weeks.

    [[chunk 0]]

    Actemra - Polyarticular/Oligoarticular JIA: Route: IV; ≥2 years: <30 kg 10 mg/kg every 4 weeks; ≥30 kg 8 mg/kg every 4 weeks.

    [[chunk 1]]

    Actemra - Polymyalgia Rheumatica: Route: IV; 8 mg/kg every 4 weeks.

    [[chunk 1]]

    Actemra - Rheumatoid Arthritis: Route: IV; ≥18 years 8 mg/kg (max 800 mg) every 4 weeks.

    [[chunk 1]]

    Actemra - Systemic JIA: Route: IV; ≥2 years: <30 kg 12 mg/kg every 2 weeks; ≥30 kg 8 mg/kg every 2 weeks.

    [[chunk 2]]

    Adcetris - Selected B‑ and T‑cell lymphoma indications: Route: IV; typical dosing 1.8 mg/kg (up to 180 mg) every 3 weeks; alternative schedules for specific indications as listed.

    [[chunk 2]]

    Alyglo (IVIG) - Selected immunologic/neurologic indications: Route: IV; examples: CIDP initial 2 g/kg divided over 2–5 days then maintenance 1 g/kg every 3 weeks; Kawasaki (<18 years) 2 g/kg single dose; other indication‑specific regimens as listed.

    [[chunk 6]]

    inv-02: Alymsys / Bevacizumab dosing limits

    Covered when drug is used for the specified diagnosis at or below the listed maximum dosing regimen

    Alymsys (Bevacizumab-maly) — oncology and ophthalmic indications: Examples of maximum dosing regimens: CNS cancer IV 10 mg/kg every 2 weeks; hepatocellular carcinoma IV 15 mg/kg every 3 weeks; colorectal cancer IV 10 mg/kg every 2 weeks; ovarian/other cancers IV 15 mg/kg every 3 weeks; intravitreal DME 1.5 mg every 4 weeks; intravitreal neovascular AMD 1.25 mg every 4 weeks or 2.5 mg every 4 weeks for defined courses; ROP (<18 years) intravitreal 0.625 mg single dose; small bowel adenocarcinoma IV 5 mg/kg q2w or 7.5 mg/kg q3w — each indication subject to its listed maximum regimen.dose and frequency limits as listed

    [[chunk 19],[chunk 21],[chunk 37]]

    inv-03: Asceniv (IVIG) dosing limits

    Covered when IVIG is administered for the specified diagnosis at or below the listed maximum dosing regimen

    Asceniv (IVIG) — per‑indication dosing examples: Multiple IV dosing regimens by diagnosis: e.g., Acquired red cell aplasia 2 g/kg per treatment divided over 2–5 days; Guillain‑Barré 2 g/kg divided over 1–5 days; CIDP initial 2 g/kg divided over 2–5 days with maintenance 1 g/kg every 3 weeks; Hemolytic disease of the newborn 1 g/kg single dose (repeat in 12 hours if needed); Neonatal hemochromatosis maternal prophylaxis 1 g/kg weekly beginning week 18 until delivery; many other diagnosis‑specific regimens as listed.dose and frequency limits as listed

    [[chunk 24],[chunk 26],[chunk 28],[chunk 31],[chunk 33],[chunk 35]]

    inv-04: Other listed specialty medications dosing limits

    Covered when used for the specified diagnosis at or below the listed dosing regimen

    Aukelso / Denosumab products — bone and metastatic indications: Subcutaneous dosing examples: Giant cell tumor of bone 120 mg on days 1, 8, 15 then 120 mg every 4 weeks; hypercalcemia of malignancy 120 mg schedule; osteoporosis/osteopenia in systemic mastocytosis 60 mg every 6 months; prevention of skeletal‑related events 120 mg every 4 weeks — per indication schedules apply.specified schedule per indication

    [[chunk 36]]

    Avastin / Bevacizumab — oncology and ophthalmology: IV and intravitreal regimens by indication: IV examples include ampullary adenocarcinoma 5 mg/kg q2w, cervical cancer 15 mg/kg q3w, colorectal 10 mg/kg q2w; intravitreal examples include DME 1.5 mg q4w, RVO/neovascular AMD 1.25–2.5 mg q4w; pediatric ROP intravitreal 0.625 mg single dose — follow indication‑specific maximums.specified dose/frequency per indication

    [[chunk 37]]

    inv-05: Diagnosis-specific maximum dosing/regimen limits

    Coverage is aligned to the listed diagnosis-specific maximum dosing regimens (examples below).

    Denosumab group (multiple biosimilars) — selected examples: Examples: 120 mg on days 1, 8, 15 then 120 mg every 4 weeks for giant cell tumor of bone; 60 mg SC every 6 months for osteoporosis indications; 120 mg every 4 weeks for prevention of skeletal‑related events — follow the per‑indication schedule shown.

    [[chunk 36],[chunk 54]]

    Infliximab biosimilars (Avsola/Inflectra) — immune/inflammatory indications: Typical induction/maintenance examples: initial 5 mg/kg weeks 0,2,6 then maintenance 5 mg/kg q6–8 weeks with maximum maintenance/induction doses up to 10 mg/kg or adjusted intervals for incomplete response per indication.

    [[chunk 41],[chunk 42],[chunk 190]]

    Tocilizumab biosimilars (Avtozma) — rheumatologic indications: IV dosing examples include cytokine release syndrome weight‑based limits (pediatric and adult bands), giant cell arteritis 6 mg/kg q4w, RA 8 mg/kg q4w (max 800 mg), and pediatric JIA weight‑based dosing — follow listed limits.

    [[chunk 46]]

    Belimumab (Benlysta) IV — SLE/Lupus nephritis: Initial: 10 mg/kg every 2 weeks for 3 doses; maintenance: 10 mg/kg every 4 weeks (IV route, ≥5 years where specified).age >=5 years

    [[chunk 54]]

    inv-06: Diagnosis-specific maximum dosing regimens (excerpt)

    Covered when dosing and indication match the diagnosis-specific maximum dosing regimens listed

    Belimumab (Benlysta) IV for SLE/Lupus nephritis: Initial: 10 mg/kg every 2 weeks for 3 doses; Maintenance: 10 mg/kg every 4 weeks.age >=5 years

    [[chunk 54]]

    Denosumab biosimilars — osteoporosis vs bone metastasis/GCT: Osteoporosis: 60 mg SC every 6 months; Giant cell tumor/hypercalcemia/bone metastases: 120 mg days 1,8,15 then 120 mg every 4 weeks as indicated.varies by indication

    [[chunk 54],[chunk 36]]

    Eculizumab biosimilar (BKEMV) — aHUS/gMG/PNH examples: Adult initial/maintenance example for aHUS: initial 900 mg weekly x4 then 1200 mg q2w maintenance; pediatric weight‑banded schedules provided.weight-based pediatric regimens provided

    [[chunk 66]]

    Bivigam IVIG — typical regimens: Typical initial 2 g/kg divided over 2–5 days; maintenance regimens vary by condition (e.g., 1 g/kg q3w, 800 mg/kg q3w) — follow per‑diagnosis limits.weight-based dosing where indicated

    [[chunk 66]]

    OnabotulinumtoxinA (Botox) — selected indications: Indication‑specific unit maximums and minimum re‑treatment intervals (e.g., chronic migraine 155 U per treatment q≥12 weeks; cervical dystonia up to 400 U per treatment q≥12 weeks; other indications with age/weight caps).age/weight thresholds where specified; 12‑week minimum

    [[chunk 72]]

    inv-07: Botox dosing limits

    Botox (OnabotulinumtoxinA) quantity limits by indication:

    Excessive Salivation: Injection 100 Units per treatment; may re‑treat no sooner than every 12 weeks.100 Units per treatment; 12‑week minimum

    [[chunk 72]]

    Facial Myokymia / First Bite Syndrome / Focal Hand Dystonia: Adults ≥18 years up to 400 Units per treatment; pediatric <18 yrs <34 kg 10 Units/kg per treatment; ≥34 kg 340 Units per treatment; may re‑treat no sooner than every 12 weeks.400 U adult; pediatric: 10 U/kg or 340 U cap; 12‑week minimum

    [[chunk 72]]

    inv-08: Botulinum and spasticity dosing limits

    Other botulinum products and indications (selected):

    Hemifacial Spasm (Botox): Intramuscular 100 Units per treatment; may re‑treat no sooner than every 12 weeks.100 Units; 12‑week minimum

    [[chunk 73]]

    Overactive Bladder (Botox): Intramuscular ≥18 years 100 Units per treatment; may re‑treat no sooner than every 12 weeks.100 Units; 12‑week minimum

    [[chunk 76]]

    Primary Axillary Hyperhidrosis (Botox): Intradermal ≥18 years 50 Units per axilla; may re‑treat no sooner than every 12 weeks.50 U per axilla; 12‑week minimum

    [[chunk 76]]

    Dysport — selected indications: Examples: Blepharospasm 120 Units per affected eye; Cervical dystonia up to 1000 Units divided; Primary axillary hyperhidrosis 200 Units per axilla; upper/lower limb spasticity up to 1500 Units total per treatment — all with ≥12‑week minimum re‑treatment intervals.varies by product/indication; 12‑week minimum

    [[chunk 85],[chunk 86]]

    Upper or Lower Limb Spasticity (Botox/Dysport): Adult and pediatric weight‑based and maximum total dose rules apply (see product‑specific limits); may re‑treat no sooner than every 12 weeks.varies by product/age/weight; 12‑week minimum

    [[chunk 76],[chunk 86]]

    inv-09: Biologics and specialty medication dosing limits

    Selected biologics / specialty agents and their maximum dosing regimens:

    Briumvi (Ublituximab-xiiy): IV first infusion 150 mg once; second infusion 450 mg 2 weeks after first; subsequent infusion 450 mg every 24 weeks.150 mg then 450 mg; maintenance every 24 weeks

    [[chunk 77]]

    Byooviz (Ranibizumab-nuna): Intravitreal 0.5 mg per affected eye every month (~28 days) for retinal indications; may dose less frequently after initial monthly doses where noted.0.5 mg monthly

    [[chunk 78]]

    Cimerli (Ranibizumab-eqrn): Intravitreal 0.3–0.5 mg per affected eye every month depending on indication (0.3 mg for diabetic macular edema/retinopathy; 0.5 mg for some AMD indications).0.3–0.5 mg monthly

    [[chunk 78]]

    Cosentyx IV (Secukinumab): IV initial 6 mg/kg on week 0; maintenance 1.75 mg/kg every 4 weeks (max maintenance 300 mg per infusion) for ankylosing spondylitis/psoriatic arthritis.6 mg/kg initial; 1.75 mg/kg maintenance up to 300 mg

    [[chunk 81]]

    inv-10: Immunoglobulin and oncology dosing limits

    Immunoglobulin and oncology agent dosing limits:

    Cutaquig / Cuvitru (SCIG) — prophylaxis and PID: Measles prophylaxis: 400 mg/kg once as soon as possible and within 6 days of exposure; primary immunodeficiency maintenance SC 347 mg/kg weekly (based on IVIG 800 mg/kg q3w) with flexible intervals if weekly dose maintained.400 mg/kg single dose (prophylaxis); 347 mg/kg weekly for PID

    [[chunk 81],[chunk 82]]

    Cyramza (Ramucirumab): IV dosing varies by indication (e.g., 8 mg/kg q2w for colorectal and many cancers; 10 mg/kg q2–3w for others) — follow indication‑specific maximums.8–10 mg/kg depending on indication

    [[chunk 82],[chunk 83]]

    Daratumumab (Darzalex) IV / Darzalex Faspro SC: IV daratumumab 16 mg/kg per dose with regimen‑specific schedules; Faspro SC 1800/30,000 mg‑units per dose with regimen‑specific schedules.16 mg/kg IV; 1800/30,000 mg‑units SC

    [[chunk 83],[chunk 84]]

    inv-11: Enhertu dosing

    Enhertu dosing limits across listed tumor types:

    Enhertu standard dosing: IV 5.4 mg/kg every 3 weeks for many listed indications (breast, colorectal, bladder, pancreatic, ovarian, NSCLC, others); select indications (esophageal/gastric GEJ, salivary gland tumor) use 6.4 mg/kg every 3 weeks — follow the indication‑specific maximum.5.4 mg/kg q3w typical; 6.4 mg/kg q3w for some indications

    [[chunk 87],[chunk 90],[chunk 91]]

    inv-12: Medication-specific maximum dosing (partial entries)

    Covered when dosing does not exceed the listed maximum dosing regimen for the specified diagnosis (entries shown are partial):

    Entyvio (Vedolizumab) for Crohn's Disease: IV 300 mg at weeks 0, 2, and 6 (induction), then 300 mg every 8 weeks for maintenance.300 mg induction; q8w maintenance

    [[chunk 92]]

    Enhertu for NSCLC (example): IV 5.4 mg/kg every 3 weeks.5.4 mg/kg q3w

    [[chunk 90]]

    Eylea (Aflibercept) for DME (example): Intravitreal 2 mg per affected eye every 4 weeks for initial dosing/maintenance as specified.2 mg per eye q4w

    [[chunk 98]]

    Flebogamma DIF for CIDP (example): IV initial 2 g/kg divided over 2–5 days; maintenance 1 g/kg divided over 1–2 days every 3 weeks.2 g/kg initial; 1 g/kg q3w maintenance

    [[chunk 99],[chunk 104]]

    Eculizumab group (example) — aHUS: Adult initial 900 mg weekly x4 then 1200 mg every 2 weeks starting week 5; pediatric weight‑banded schedules provided.900 mg weekly x4 then 1200 mg q2w (adult)

    [[chunk 66]]

    inv-13: Diagnosis-specific maximum dosing regimens (Quantity limits)

    Covered when dosing does not exceed the listed maximum dosing regimens for the specified diagnosis

    Flebogamma DIF — selected diagnoses and maximums: Examples include: Renal transplant ABO incompatibility 2 g/kg per dose; Secondary immunosuppression 800 mg/kg every 3 weeks; Solid organ transplantation for allosensitized members 3 g/kg divided over 2–5 days (max 1 g/kg/day) every 2–4 weeks; Stevens‑Johnson/TEN 3 g/kg divided over 1–5 days; CIDP and other neurologic/immune indications with listed initial and maintenance regimens.see text

    [[chunk 108],[chunk 109]]

    Gammagard Liquid — selected diagnoses and regimens: Examples include: Acquired red cell aplasia 2 g/kg divided over 2–5 days; CIDP initial 2 g/kg then maintenance 1 g/kg q3w; ITP 1 g/kg daily x2 or 400 mg/kg daily x5; multiple other diagnosis‑specific IV regimens as listed.see text

    [[chunk 114],[chunk 116],[chunk 119],[chunk 121]]

    Gammagard S/D — selected diagnoses: Many regimens mirror Gammagard Liquid: CIDP initial 2 g/kg over 2–5 days then 1 g/kg maintenance q3w; Guillain‑Barré 2 g/kg over 1–5 days; ITP and hematologic regimens as listed.see text

    [[chunk 127],[chunk 128]]

    Pegfilgrastim biosimilars (Fulphila, Fylnetra) — ARS and febrile neutropenia: ARS: adults ≥18 years 6 mg weekly for 2 doses (pediatric weight bands provided); prevention of febrile neutropenia: adults 6 mg once per chemotherapy cycle; do not administer between 14 days prior to and 24 hours after chemotherapy; weight/age banded maximums apply.timing restriction relative to chemotherapy

    [[chunk 121],[chunk 112]]

    inv-14: Per-product, per-indication maximum IVIG dosing (examples)

    Covered when dosing does not exceed the listed product- and indication-specific maximum regimens (route; dose; frequency) shown below.

    Gammagard Liquid — examples: Stiff‑Person syndrome: IV 2 g/kg divided over 2–5 days every month; SLE: IV 2 g/kg divided over 2–5 days every 4 weeks; Varicella prophylaxis: IV 400 mg/kg once; Tetanus (if TIG unavailable): IV 400 mg/kg once.per chunk 126
    Gammagard S/D — examples: CIDP: initial 2 g/kg over 2–5 days; maintenance 1 g/kg over 1–2 days every 3 weeks; ITP regimens and Guillain‑Barré 2 g/kg over 1–5 days; other IV regimens as listed.per chunks 127–136
    Gammaked — examples: Kawasaki (<18 years): IV 2 g/kg single dose; Neonatal hemochromatosis prophylaxis maternal 1 g/kg weekly from week 18 until delivery; Guillain‑Barré IV 2 g/kg over 1–5 days; multiple other diagnosis‑specific regimens.per chunks 138–145

    inv-15: Product-specific maximum dosing regimens

    Maximum dosing regimens for specified diagnoses and IVIG products (effective 4/1/2026):

    Gammaked dosing examples: Examples include: Lambert‑Eaton 2 g/kg IV over 2–5 days (repeat q4–12 weeks); Measles prophylaxis 400 mg/kg once within 6 days; Multifocal motor neuropathy 2 g/kg then 1–2 g/kg q2–6 weeks (max 1 g/kg/day); Primary immunodeficiency 800 mg/kg every 3 weeks; many other diagnosis‑specific regimens as listed.

    [[chunk 144],[chunk 145]]

    inv-16: Gammaplex maximum dosing regimens

    Gammaplex IVIG maximum dosing regimens by diagnosis:

    Gammaplex dosing examples: Selected entries: Acquired red cell aplasia 2 g/kg per treatment divided over 2–5 days; CIDP initial 2 g/kg then maintenance 1 g/kg q3w; Guillain‑Barré 2 g/kg over 1–5 days; BMT/HSCT 800 mg/kg every week; Multiple myeloma 800 mg/kg every 3 weeks; many other diagnosis‑specific regimens as listed.

    [[chunk 151],[chunk 152],[chunk 153]]

    inv-17: Gamunex-C maximum dosing regimens

    Gamunex‑C IVIG maximum dosing regimens by diagnosis:

    Gamunex‑C dosing examples: Examples include: Acquired red cell aplasia 2 g/kg per treatment divided over 2–5 days; CIDP initial 2 g/kg then maintenance 1 g/kg q3w; Guillain‑Barré 2 g/kg over 1–5 days; BMT/HSCT 800 mg/kg every week; multiple additional diagnosis‑specific regimens as listed.

    [[chunk 162],[chunk 163]]

    inv-18: Diagnosis-specific maximum dosing limits (selected examples)

    Dosing limits for Gammaplex/Gamunex‑C and other specialty drugs effective 4/1/2026. Covered when dosing does not exceed the listed maximum regimen per diagnosis.

    Toxic Shock Syndrome: Gammaplex/Gamunex‑C: 2 g/kg divided over 1–5 consecutive days.2 g/kg

    [[chunk 162]]

    Varicella Prophylaxis: Gammaplex/Gamunex‑C: 400 mg/kg once as soon as possible and within 6–10 days after exposure (per entry).400 mg/kg once

    [[chunk 162],[chunk 168]]

    CIDP: Gamunex‑C: Initial 2 g/kg divided over 2–5 days; maintenance 1 g/kg divided over 1–2 days every 3 weeks.Initial 2 g/kg; maintenance 1 g/kg

    [[chunk 164]]

    Primary Immunodeficiency: Gamunex‑C: 800 mg/kg every 3 weeks (IV or SC) or SC weekly equivalents as listed.800 mg/kg every 3 weeks

    [[chunk 171]]

    Solid Organ Transplantation (allosensitized): Gamunex‑C: 3 g/kg divided over 2–5 days (max 1 g/kg/day) every 2–4 weeks.3 g/kg

    [[chunk 172]]

    inv-19: Maximum dosing regimens by drug and indication (partial list)

    Covered when administered at or below the listed maximum dosing regimens for the specified indications:

    Herzuma / Kanjinti (Trastuzumab biosimilars) — breast and other tumors: IV regimens include: 4 mg/kg IV loading (7‑day cycle) then 2 mg/kg weekly maintenance OR 8 mg/kg loading (21‑day cycle) then 6 mg/kg q3w maintenance; allowed up to 52 weeks for adjuvant/neoadjuvant uses; intrathecal/intraventricular 150 mg weekly for leptomeningeal disease where specified.cycle‑specific dosing; up to 52 weeks where allowed

    [[chunk 180],[chunk 200]]

    Hizentra / Hyqvia (SCIG) — CIDP / PID examples: Hizentra CIDP SC: 400 mg/kg over 1–2 days every week; Hizentra PID SC: 365 mg/kg weekly (weekly equivalence based on IVIG 800 mg/kg q3w). Hyqvia: 1 g/kg every 3 weeks for CIDP after ramp‑up; PID 800 mg/kg q3w after ramp‑up.365–400 mg/kg weekly equivalence; 1 g/kg q3w for Hyqvia

    [[chunk 182],[chunk 183],[chunk 184]]

    Inflectra / Avsola (Infliximab biosimilars) — rheumatologic/IBD indications: Typical induction 5 mg/kg at weeks 0,2,6 with maintenance every 6–8 weeks; maximum maintenance/induction dosing allowances up to 10 mg/kg or altered intervals for incomplete responders as listed per indication.indication‑specific maximum maintenance doses listed

    [[chunk 190],[chunk 192]]

    Jobevne / Mvasi (Bevacizumab biosimilars) — oncology and ophthalmic: IV or intravitreal dosing by indication: IV examples include 5–15 mg/kg q2–3w depending on tumor type; intravitreal 1.25–1.5 mg q4w for retinal indications; pediatric ROP intravitreal 0.625 mg single dose — follow per‑indication maximums.varies by indication

    [[chunk 194],[chunk 197],[chunk 198]]

    inv-20: Indication-specific quantity limits (selected entries)

    Coverage is limited to the listed diagnoses and maximum dosing regimens below.

    Jobevne (Bevacizumab‑nwgd) — Vulvar Carcinoma: Route: IV; Dose: 15 mg/kg every 3 weeks.15 mg/kg q3w

    [[chunk 198]]

    Jubbonti / Jubbonti (Denosumab‑bbdz) — Osteoporosis/Bone indications: Route: SC; Dose: 60 mg every 6 months for osteoporosis and specified cancer‑related prevention indications.60 mg q6mo

    [[chunk 198]]

    Kanjinti (Trastuzumab‑anns) — breast and CNS indications: IV regimens include 4 mg/kg once then 2 mg/kg weekly OR 8 mg/kg once then 6 mg/kg q3w; intrathecal 150 mg weekly for leptomeningeal disease; allowed up to 52 weeks for certain adjuvant/neoadjuvant uses.varies by regimen; up to 52 weeks where specified

    [[chunk 200]]

    Keytruda (Pembrolizumab) — multiple cancers: IV typical adult dosing 200 mg q3w or 400 mg q6w; pediatric weight‑based dosing examples 2 mg/kg q3w (max 200 mg) for <18 yrs — follow indication‑specific dosing limits.200 mg q3w or 400 mg q6w (adult)

    [[chunk 215]]

    Lemtrada (Alemtuzumab) — Multiple Sclerosis: IV: First course 12 mg daily x5 days; subsequent course 12 mg daily x3 days given ~12 months after prior course.course‑based dosing

    [[chunk 214]]

    Lucentis (Ranibizumab) — retinal indications: Intravitreal dosing examples: 0.3 mg monthly for DME/DR; 0.5 mg monthly for neovascular AMD; may be dosed less frequently after initial monthly doses per indication.0.3–0.5 mg monthly

    [[chunk 214],[chunk 215]]

    inv-21: Medication-specific maximum dosing regimens by diagnosis (partial)

    Maximum dosing regimens specified for listed drugs when used for the named diagnoses (effective 4/1/2026).

    Octagam — selected dosing examples: Multiple Myeloma: IV 800 mg/kg every 3 weeks; Myasthenia gravis exacerbation: IV 2 g/kg divided over 1–5 days; neonatal hemochromatosis prophylaxis maternal 1 g/kg weekly from week 18 until delivery; varicella prophylaxis 400 mg/kg once within 10 days of exposure; Stevens‑Johnson/TEN 3 g/kg divided over 1–5 days — follow per‑diagnosis limits.dosage per kg or fixed

    [[chunk 234],[chunk 235],[chunk 240]]

    Ogivri/Ontruzant (trastuzumab biosimilars): Breast and other malignancies: IV 4 mg/kg loading (7‑day) then 2 mg/kg weekly maintenance OR 8 mg/kg loading (21‑day) then 6 mg/kg q3w; intrathecal 150 mg weekly for leptomeningeal dosing where listed; allowed up to 52 weeks in certain adjuvant/neoadjuvant uses.cycle‑specific dosing

    [[chunk 240],[chunk 244],[chunk 246]]

    Omlyclo (Omalizumab) — allergy/asthma/CRSwNP/urticaria: Dosing varies by age/weight and indication (examples: chronic spontaneous urticaria ≥12 years 300 mg q4w; CRSwNP ≥18 years 600 mg q2w; pediatric asthma and other indications per weight bands) — follow listed age/weight dosing tables.age and weight‑based dose ranges

    [[chunk 244]]

    Opdivo (Nivolumab) — oncology indications: Common IV regimens include 240 mg q2w or 480 mg q4w for adults; pediatric and weight‑based schedules (e.g., <40 kg 3–6 mg/kg q2–4w) and indication‑specific initial/maintenance alternatives are provided — adhere to the per‑indication limits.fixed or weight‑based dosing per indication

    [[chunk 244],[chunk 247]]

    No explicit exclusions are listed in the coverage criteria excerpts. The document segment focuses on defining maximum dosing regimens and intervals by diagnosis and product (effective 4/1/2026) rather than enumerating conditions or populations that are categorically excluded from coverage. Refer to the listed indication-specific dosing lines (examples: tocilizumab entries for cytokine release syndrome, Actemra for giant cell arteritis, and multiple IVIG product lines) for the scope of the dose limits provided.

    Administration or requests that would result in doses, dose frequencies, or re-treatment intervals that exceed the stated maximum regimens for each indication are not supported by the quantity limits shown. For example, intravitreal and IV agents have explicit per‑indication maximums (e.g., intravitreal Alymsys 1.25–1.5 mg every 4 weeks; Asceniv IVIG typically 2 g/kg divided over 2–5 days for many indications) and use beyond those listed dose/frequency limits is outside the dosing limits provided.

    Any dosing request that exceeds the specified diagnosis‑specific maximum dosing regimens in this section (for example, higher mg/kg dosing, additional total doses beyond the stated course, or shorter re‑treatment intervals than the minimums listed) is not aligned with the listed quantity limits and may be subject to quantity‑limit enforcement or denial.

    Pediatric ROP intravitreal dose
    <18 years: 0.625 mg in the affected eye(s) for 1 dose
    Agent exampleAlymsys (bevacizumab-maly) — Retinopathy of Prematurity intravitreal dosing specified as 0.625 mg single dose in affected eye(s)
    FrequencySingle dose; no repeated dosing listed for ROP in this entry
    Adult intravitreal dosing for Neovascular AMD / Diabetic Macular Edema
    Adult intravitreal dose range≥18 years: 1.25–1.5 mg in the affected eye(s) every 4 weeks depending on product/indication (examples: 1.25 mg for bevacizumab; 1.5 mg noted for some agents)
    Neovascular AMD exampleAlymsys (bevacizumab-maly) intravitreal: ≥18 years 1.25 mg every 4 weeks (also 2.5 mg every 4 weeks for select regimens)
    Diabetic Macular Edema exampleAlymsys (bevacizumab-maly) DME: ≥18 years 1.5 mg every 4 weeks
    Belimumab IV maintenance dosing
    Belimumab IV maintenance10 mg/kg every 4 weeks (maintenance) after initial 10 mg/kg every 2 weeks x3 doses
    Induction scheduleInitial: 10 mg/kg every 2 weeks for 3 doses (per SLE/lupus nephritis entry)
    Age thresholdIV dosing specified for ≥5 years where indicated
    Denosumab (many biosimilars) osteoporosis dosing
    Osteoporosis dosing (denosumab)60 mg subcutaneous every 6 months for osteoporosis/postmenopausal/men/glucocorticoid-induced osteoporosis
    Product examplesListed denosumab biosimilars include Bildyos, Bosaya, others with 60 mg q6 months for osteoporosis
    Effective dateDosing entries effective 4/1/2026 as shown in the policy
    Denosumab (GCT, hypercalcemia, bone mets) dosing
    High‑dose/oncology bone indications120 mg subcutaneous on days 1, 8, and 15 of the first month, then 120 mg every 4 weeks for giant cell tumor of bone, hypercalcemia of malignancy, and bone metastases indications
    Alternate osteoporosis scheduleFor osteoporosis-related indications some denosumab products use 60 mg subcutaneously every 6 months (separate entry)
    Multiple biosimilarsSeveral denosumab biosimilars (Bilprevda, Bomyntra, others) list the 120 mg q4w schedule for bone metastases/GCT indications
    Bivigam IVIG typical initial dosing
    Typical IVIG initial dosing (Bivigam example)2 g/kg divided over 2–5 consecutive days for initial treatment (varies by indication)
    Maintenance examplesMaintenance regimens vary by condition (e.g., 1 g/kg every 2–6 weeks; 800 mg/kg every 3 weeks) as listed per indication
    Special prophylaxis dosingIVIG prophylaxis examples include 400 mg/kg once within defined exposure windows (e.g., measles/varicella) per product entries
    OnabotulinumtoxinA chronic migraine dosing
    Chronic migraine (OnabotulinumtoxinA)155 Units per treatment; may be re-treated no sooner than every 12 weeks
    Route and intervalIntramuscular administration with a minimum 12‑week re‑treatment interval
    Age thresholdChronic migraine dosing specified for ≥18 years
    Minimum re-treatment interval
    Minimum re‑treatment interval for botulinum toxins12 weeks between treatments for botulinum toxin products (minimum) — applies across listed indications
    Cumulative dose considerationsSome indications list maximum total units per treatment or per interval (e.g., adult max 400 Units for several indications)
    Applies to multiple productsInterval guidance appears for Botox, Dysport, Myobloc and other botulinum products in the policy
    Briumvi maintenance interval
    Briumvi maintenance interval450 mg IV every 24 weeks after initial two‑dose series (first infusion 150 mg, second infusion 450 mg at 2 weeks)
    Initial seriesFirst infusion: 150 mg once; Second infusion: 450 mg given 2 weeks after the first
    Maintenance startSubsequent 450 mg infusions begin 24 weeks after the first infusion and continue every 24 weeks
    Age/Weight thresholds
    Common age thresholdsExamples of age thresholds used across entries: ≥18 years and <18 years (pediatric) with product-specific distinctions)
    Weight bands examplesPolicy examples include weight bands such as 30–<40 kg, 20–<30 kg, <30 kg vs ≥30 kg for pediatric dosing
    Product‑specific age/weight rulesMany agents (e.g., tocilizumab, pegfilgrastim, botulinum toxins) specify both age and weight bands to determine dosing
    Timing relative to chemotherapy
    Timing relative to chemotherapy (pegfilgrastim guidance)Do not administer between 14 days prior to and 24 hours after administration of chemotherapy (timing restriction for pegfilgrastim products)
    RationalePolicy lists explicit chemotherapy-relative timing to avoid inappropriate administration windows
    Product examplesFulphila/Fylnetra and other pegfilgrastim biosimilars reference these timing restrictions in dosing entries
    Hizentra weekly dose equivalence
    Hizentra weekly equivalence365 mg/kg every week (SC) as the weekly equivalent based on maximum IVIG 800 mg/kg every 3 weeks
    Flexible intervalsProvided the total weekly dose is maintained, dosing interval may vary from daily up to biweekly
    Indication contextHizentra SC dosing guidance is presented for primary immunodeficiency and related uses
    Age/weight thresholds
    Age/weight distinctions repeatedPolicy frequently differentiates dosing for ≥18 years versus <18 years and uses weight‑based pediatric dosing caps (examples in tocilizumab, pembrolizumab, pegfilgrastim entries)
    Pediatric mg/kg capsExamples include pediatric mg/kg caps and weight banded dosing for agents such as pembrolizumab and pegfilgrastim
    Documentation implicationWhen weight- or age-based dosing applies, patient age and weight should be documented to support the requested regimen
    • Prior authorization must align with the product- and diagnosis-specific maximum dosing regimens and intervals.
    • For specialty IVIG products, use the product-specific dosing/regimen when submitting prior authorization requests (see IVIG product entries with their per-diagnosis regimens).
    Note

    Prior authorization not specified in excerpt

    The excerpted quantity limits list maximum regimens and effective date but do not always state explicit prior authorization or denial processes within these chunks. Where PA or denial rules are not specified in this excerpt, providers must still follow the dosing limits and supply documentation when requesting exceptions.

    • Not present in this excerpt: explicit prior authorization policy language or step therapy directions for many entries — the document provides quantity limits and effective date (4/1/2026) as the authoritative dosing constraints.
    • No explicit denial triggers are listed in these chunks; however, requests inconsistent with the listed route, dose, frequency, or interval may be subject to denial under broader utilization management rules.
    Documentation Required

    Required documentation for dosing

    Document the diagnosis and the exact dosing regimen requested. For weight-based dosing, include the patient’s current weight and the mg/kg calculations supporting the requested dose. Provide indication-specific clinical rationale when requesting doses or intervals outside the listed maximums.

    • Required documentation: diagnosis, intended dosing regimen (including weight and mg/kg math for weight-based dosing), frequency, and planned re-treatment interval.
    • When requesting IVIG, indicate the specific product and the product-specific dosing schedule being used.
    • Prescriptions or prior authorization requests should reference the applicable diagnosis entry and the exact regimen from the quantity limits table.
    Documentation Required

    Use product-specific dosing when requesting IVIG

    Use the product-specific dosing regimens listed for IVIG and other immune globulin products when requesting authorization or submitting claims. The table lists many IVIG products with diagnosis-specific maximum dosing regimens (for example, 2 g/kg per treatment divided over 2–5 days for multiple indications; maintenance schedules vary by product and diagnosis).

    • When seeking authorization for IVIG, reference the named product (e.g., Gammagard, Gamunex-C, Flebogamma DIF, Octagam, etc.) and the diagnosis-specific dosing/regimen from the quantity limits.
    • Provide dosing interval and maintenance plan consistent with the product-specific entry in the limits table.
    Note

    Dosing limits (informational)

    These dosing limits are informational and define the payer’s maximum allowed regimens effective 4/1/2026. They should be used for treatment planning and prior authorization requests but do not, in isolation, replace full PA or coverage policy language that may exist elsewhere.

    • Dosing limits include effective date (4/1/2026) and per-diagnosis maximums; consult full policy or PA rules for procedural requirements.
    • No step therapy requirements are specified in this excerpt.
    Denial Risk

    Dose/Interval overage

    Requests that exceed listed dose, frequency, or re-treatment intervals — for example higher mg/kg dosing, more frequent maintenance, or re-treatment sooner than the minimum interval (such as botulinum products before 12 weeks) — may be denied or require a detailed prior authorization and supporting clinical documentation.

    • Examples of potential overage issues: dose exceeding the per-treatment maximum, more frequent dosing than allowed, or re-treatment earlier than the specified interval.
    • When an overage is clinically justified, include robust documentation supporting the deviation in the PA request.
    Step Therapy

    Step therapy not specified

    There are no explicit step therapy requirements or step edits described in these chunks. If step therapy is relevant for a particular medication it is not specified within this excerpt, and providers should consult the complete policy or PA system for any step requirements.

    • Step therapy not specified in this excerpt.
    Billing Rule

    Provider action checklist

    Summary action checklist for providers: follow the listed dosing/regimen limits; document diagnosis, weight, and mg/kg calculations when applicable; use product-specific IVIG dosing when applicable; and submit prior authorization requests that match the requested dosing if you intend to exceed limits or if PA is required by your payer system.

    • Adhere to maximum doses, frequencies, and minimum re-treatment intervals shown in the quantity limits effective 4/1/2026.
    • Include diagnosis, dosing details, patient weight for weight-based dosing, and clinical justification in PA requests.
    • If no explicit PA is present in this excerpt, verify PA requirements in the payer’s authorization system; do not assume absence of PA from this dosing table alone.
    Minimum re‑treatment interval commonly 12 weeks for botulinum toxins, which informs 12‑week cumulative calculations
    Product examplesApplies across botulinum toxin products (Botox, Dysport, Myobloc) where per‑interval maxima are specified
    Briumvi dosing schedule
    Briumvi dosing schedule (initial + maintenance)Initial infusion 150 mg once; second infusion 450 mg at 2 weeks; then 450 mg every 24 weeks for maintenance
    Maintenance intervalMaintenance infusions occur every 24 weeks starting 24 weeks after the first infusion
    Documentation notePrescribers should document regimen and schedule to match the specified infusion dosing (initial + maintenance)
    Initial vs Maintenance dosing
    Initial vs maintenance dosing conceptSeveral entries specify higher initial (induction) dosing followed by lower‑dose maintenance (examples: IVIG 2 g/kg induction then 1 g/kg maintenance; Entyvio induction then q8w maintenance)
    IVIG exampleCIDP: initial 2 g/kg divided over 2–5 days, maintenance 1 g/kg every 3 weeks (per multiple IVIG products)
    Entrust documentationInduction and maintenance schedules should be matched in authorization requests
    Weight-based dosing
    Weight-based dosing formatMany immune globulin and oncology regimens are specified per kg body weight (e.g., IVIG initial 2 g/kg divided over 2–5 days; tocilizumab 8 mg/kg etc.)
    ExamplesFlebogamma/Flebogamma DIF/Gammagard entries list 2 g/kg, 800 mg/kg, 1 g/kg regimens for various diagnoses
    Calculation implicationPatient weight must be documented to calculate mg/kg or g/kg dosing accurately
    IVIG products
    IVIG products listedNamed IVIG products in the policy include Gammaked, Gammaplex, Gamunex‑C, Octagam and others with diagnosis‑specific dosing regimens
    Per‑product dosing differencesEach IVIG product lists multiple indication‑specific maximum regimens (dose, frequency, route) effective 4/1/2026
    Common dosesTypical IVIG regimens include 2 g/kg induction, 1 g/kg maintenance, 800 mg/kg q3w and other product-specific schedules
    IVIG weekly equivalent conversion
    IVIG weekly equivalent conversion (Hizentra)Hizentra SC: 365 mg/kg every week as the weekly equivalent based on max IVIG 800 mg/kg every 3 weeks
    Flexible schedulingIf total weekly dose is maintained, interval may be daily up to biweekly per product guidance
    Indication exampleConversion stated in context of primary immunodeficiency dosing
    Immune Globulin Intravenous (Octagam)
    Octagam dosing examplesOctagam IVIG regimens include 800 mg/kg every 3 weeks for multiple myeloma and 2 g/kg divided over 1–5 days for myasthenia gravis exacerbation, among many diagnosis‑specific schedules
    Varied regimensOctagam entries list prophylactic and therapeutic regimens (e.g., 400 mg/kg single prophylaxis doses; 3 g/kg divided regimens for select conditions)
    Effective dateEntries effective 4/1/2026
    Route of Administration
    Routes of administration notedPolicy entries explicitly state intravenous (IV), subcutaneous (SC), intravitreal, intramuscular routes associated with dosing regimens
    Examples by routeIV (IVIG, oncology biologics), SC (denosumab osteoporosis 60 mg q6mo, Hizentra SC weekly), Intravitreal (aflibercept, ranibizumab, bevacizumab) and IM/Injection (botulinum toxins)
    ImplicationRoute is required in authorization/documentation to match the listed maximum dosing regimen